678P Real-world evidence of first-line cetuximab (CX) plus paclitaxel (PX) in recurrent or metastatic squamous cell carcinoma of the head and neck (SCCHN)

E Ortega,M Plana Serrahima,V Quiroga,V Arrazubi Arrula,Beatriz Cirauqui ,Elvira Del Barco Morillo ,V Gutiérrez Calderón ,Pedro Pérez Segura ,Alberto Carral Maseda ,Manuel Conde ,Adolfo Castaño ,Isaac Ceballos Lenza ,Lara Iglesias Docampo ,Javier Salvá ,Javier Martínez Trufero ,Joaquina Martínez-Galán ,C Pena Álvarez,J Rubió-Casadevall,R Mesia Nin,M Durán Sánchez

doi:10.1016/j.annonc.2022.07.802

678P Real-world evidence of first-line cetuximab (CX) plus paclitaxel (PX) in recurrent or metastatic squamous cell carcinoma of the head and neck (SCCHN)

E Ortega, M Plana Serrahima + Show 18 more

Open Access

https://doi.org/10.1016/j.annonc.2022.07.802

Copy DOI

Journal: Annals of Oncology	Publication Date: Sep 1, 2022
License type: publisher-specific-oa

#Squamous Cell Carcinoma Of The Head And Neck #Plus Paclitaxel + Show 8 more

Abstract
Full-Text PDF
Similar Papers

Abstract

Results from a phase II trial showed efficacy of CT plus weekly PX in patients (pts) with SCCHN who are medically unfit for platinum-based (PT) chemotherapy. This study aimed to validate the efficacy of the proposed combination as first-line treatment for recurrent/metastatic SCCHN pts in the real world.

Full Text